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Abstract: 
Pharmacogenetics tests are being used increasingly to prevent rare and potentially life-threatening 
adverse drug reactions. For many tests, however, cost-effectiveness is hard to demonstrate and, 
with the exception of a few cases, widespread implementation remains a distant prospect.  Many 
orphan drugs for rare diseases are also not cost-effective but are nonetheless normally reimbursed. 
In this article, we argue that the health technology assessment of pharmacogenetics tests aimed to 
prevent rare but severe adverse drug reactions should be on a level playing field with orphan drugs. 
This is supported by a number of arguments, concerning the severity, rarity and iatrogenic nature of 
adverse drug reactions, the distribution of benefits and costs, and the preference placed on 
prevention over treatment. 
  
Article: 
Pharmacogenetics tests are being used increasingly to prevent or pre-empt rare and potentially life-
threatening adverse drug reactions (ADRs) [1].  Examples where pre-prescription genotyping is 
required or recommended by the European Medicines Agency or the US Food and Drug 
Administration (FDA) include HLA-B*57:01 for the prevention of abacavir-induced hypersensitivity 
reactions; HLA-A*15:02 to prevent Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis 
(TEN) relating to carbamazepine, and HLA-DQA1*02:01 or HLA-DRB1*07:01 to prevent lapatinib-
induced hepatotoxicity. For each of these, identified carriers may be offered alternative treatments 
with reduced risks of harm. In the case of abacavir, routine testing for HLA-B*58:01 has effectively 
eliminated hypersensitivity reactions [2]. 
However, evidence on the clinical effectiveness of pharmacogenetics testing for preventing ADRs is 
variable. While randomised controlled trials support testing in relation to treatment with abacavir 
[3], clopidogrel [4] and warfarin [5,6], the majority of labelling recommendations and actionable 
notices are based on studies of association. Moreover, evidence supporting the cost-effectiveness of 
introducing pharmacogenetics testing into clinical practice is sparse, with as few as one in ten drugs 
with FDA labels which include genetic information having associated economic data [7]. For many 
single-gene tests, cost-effectiveness is hard to demonstrate, not only because of the lack of 
definitive clinical evidence, but also because of the rarity of the ADR being avoided, the allele 
frequency, the positive and negative predictive value of testing, and the costs, effectiveness and 
safety of alternative treatment options [8]. 
Demonstration of cost-effectiveness requires that the incremental costs of testing are justified by 
the additional benefits.  In the National Health Service (NHS) in the UK, the threshold is set at 
£20,000 to £30,000 per quality-adjusted life-year (QALY) gained [9]. Health technologies are 
considered to offer good value for money if their incremental cost-effectiveness ratios (ICER) are 
below this range, but are generally not recommended for use if they are higher. For drugs associated 
with more common ADRs and with a high negative predictive value (NPV) of testing, such as in the 
example of HLA-B*57:01 genotyping prior to abacavir (ADR ~6%, NPV ~100%) [3], the number of 
patients needed to be screened is comparatively low making the test cost effective [10]. To prevent 
one case of abacavir hypersensitivity, 8 HLA-B*57:01 positive patients would be denied abacavir, and 
to identify them, 48 patients would require testing [11]. Similarly, many genetic and biomarker 
screening tests for more prevalent diseases may be cost-effective in certain populations [12-14]. 
However for the avoidance of many rare events, such as many severe ADRs, a far greater number of 
patients need to be screened, rendering the test less cost-effective. Allopurinol causes SJS/TEN in 
about 7 patients for every 10,000 treated [15]. This requires that 11,286 patients need to be 
screened for HLA-B*58:01 in order to prevent one case of ADR [16]. Consequently, at around £50 for 
a single-gene test, the screening of patients with gout is not cost-effective – either in the UK, at 
£44,954 per QALY gained [16] – or in many other jurisdictions [17-19]. 
An important consideration here concerns the distribution of costs and benefits. The great majority 
of patients tested for HLA-B*58:01 would never experience a severe ADR and so would continue on 
allopurinol with no additional health benefit from testing, but having incurred the extra cost of 
testing. Others will have their prescription unnecessarily changed to febuxostat, a more expensive, 
but possibly more effective drug for gout. As the ICER for testing is based on the average of all 
patients, it fails to reflect the distribution of costs and consequences among those tested. For every 
11,286 patient screened, all bar one will gain 0.0025 QALYs (about 1 additional quality-adjusted day) 
while costing the NHS an additional £105 over a lifetime.  The one patient who averts the ADR avoids 
losses of 3.43 QALYs, and a cost to the NHS of £17,250 [16]. 
This presents an interesting contrast with the cost-effectiveness of drugs developed for rare 
diseases. Regulation 141/2000 of the European Commission [20] defines an orphan medicinal 
product as the first to represent a satisfactory treatment (or to provide a significant additional 
benefit to an existing treatment) of a life-threatening or chronically debilitating condition affecting 
not more than five in 10,000 persons. A treatment of SJS/TEN would thus qualify for orphan 
designation (general population incidence of around 6 cases per million person-years [21]), but a 
pharmacogenetic test aimed to prevent SJS/TEN might not. This has implications in terms of the 
incentives available to manufacturers for developing interventions for rare diseases, and also in 
terms of healthcare system reimbursement. 
The similarities and differences between the treatment and prevention of rare disease are illustrated 
in Table 1, comparing genotyping for HLA-B*58:01 to prevent allopurinol induced SJS/TEN with 
afamelanotide, an orphan drug for the management of erythropoeitic protoporphyria. 
Afamelanotide has been approved in Europe and is currently reimbursed in Austria, Germany, Italy, 
Netherlands and Switzerland, and will be evaluated by the UK National Institute for Health and Care 
Excellence in May 2018. Testing for HLA-B*58:01 by contrast, is recommended by the Taiwan 
Department of Health, but not by other regulators, and is not considered to be cost-effective [16-
19]. 
-- Insert Table 1 here -- 
Orphan drugs treat the identifiable few whereas pharmacogenetic tests identify the few who are at 
risk of a rare ADR. Orphan drugs tend to be very expensive on an individual patient basis but provide 
significant health benefits to those treated [27]; whereas pharmacogenetic tests are inexpensive for 
individual patients, but expensive for populations and benefit only a small proportion of those 
tested. Because of their high costs, economic evaluations of orphan drugs often yield ICERs in the 
order of hundreds of thousands (if not millions) of pounds per QALY gained [28], far exceeding the 
cost-effectiveness threshold. Yet despite this, most orphan drugs are approved for use [29], often 
justified on the grounds of equity [30]. That is, equity considerations (a sense of distributive fairness 
in access to treatment) outweigh efficiency principles (achieving the greatest benefit from finite 
resources). 
Consequently, non-implementation of pharmacogenetic tests on the grounds of cost-ineffectiveness 
(such as HLA-B*58:01 for allopurinol), would be inconsistent with the special funding status given to 
orphan drugs [31]. While there is considerable empirical evidence showing society’s unwillingness to 
trade extensive health benefits experienced by many, for expensive benefits experienced by a few 
[32-34], there is evidence that people’s evaluation of fairness is influenced when comparing the 
benefit to an individual patient with the average cost to those who share the cost [35]. When patient 
numbers are small and the average cost to those who share the cost is small, a well-informed public 
is likely to support the funding or part-funding of effective services that may not be cost effective. 
Many rare diseases are hereditable. The lysosomal storage disorders, for which there are many 
effective, but highly expensive enzyme replacement therapies, are autosomal recessively inherited 
and affect 1 in 5,000 to 1 in 10,000 live births. The clustering of LSDs and other inherited metabolic 
disorders within families, and their early presentation in childhood are further reasons offered to 
justify funding of non-cost-effective medicines. These characteristics are considered in health 
technology assessments of orphan drugs but not of pharmacogenetics tests despite the comparable 
contexts, such as with the significant association between HLA loci (which are hereditary) and the 
predisposition of immune-mediated ADRs. Mother-to-child transmission of HIV could require both to 
be treated with abacavir, and risk ADRs if also carriers of HLA-B*57:01. Moreover, there are 
potentially important incidental findings to genotyping, both in relation to future prescriptions for an 
individual, and to family members. These are not generally considered in economic evaluations. 
ADRs are iatrogenic, and this presents a further challenge regarding social value judgements. It is 
possible that society values the benefits achieved through implementing methods to avoid 
iatrogenic harm higher than the health forgone through the disinvestment or displacement of other 
services which would be necessary to finance them within the confines of a finite budget. While 
there are no empirical data to support this, it is aligned with the safety agenda of the NHS and other 
healthcare services internationally and the notion that harm experienced through the course of 
healthcare is to be prevented at all/any (reasonable) cost.  
Preference elicitation studies indicate that for equivalent health gains, the general public strongly 
prefer prevention over cure [36]. The implied value placed on deaths avoided through preventative 
strategies is twice that of treatment policies [37]. In the context of pharmacogenetics and ADRs, and 
drawing on the comparison with orphan drugs, this might indicate an equity balance tipped in favour 
of testing over treating. 
We contend that pharmacogenetics tests aimed to prevent rare but severe and potentially life 
threatening ADRs should be on a level playing field – not only with other diagnostics in terms of 
evidential standards [38] – but also with orphan drugs used to treat rare diseases. This is supported 
by a number of arguments, concerning the severity, rarity and iatrogenic nature of ADRs, the 
distribution of benefits and costs, and the preference placed on prevention over treatment.  
 
References 
1. Yip VL, Alfirevic A, Pirmohamed M. Genetics of immune-mediated adverse drug reactions: a 
comprehensive and clinical review. Clin Rev Allergy Immunol. 2015;48(2-3):165-75. 
2. Zucman D, Truchis Pd, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for 
human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically 
mixed French HIV population. J Acquir Immune Defic Syndr. 2007;45(1):1-3. 
3. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B*5701 screening for 
hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568-79. 
4. Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, et al. Point-of-care genetic 
testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, 
proof-of-concept trial. Lancet. 2012;379(9827):1705-11. 
5. Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Li J, Rodríguez T Jr, Miller JP, 
McMillin GA, Pendleton RC, Jaffer AK, King CR, Whipple BD, Porche-Sorbet R, Napoli L, Merritt K, 
Thompson AM, Hyun G, Anderson JL, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Dávila-
Román V, Eby CS. Effect of Genotype-Guided Warfarin Dosing on Clinical Events and 
Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT 
Randomized Clinical Trial. JAMA. 2017;318(12):1115-1124. 
6. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A randomized 
trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294–303. 
7. Phillips KA, Ann Sakowski J, Trosman J, Douglas MP, Liang SY, Neumann P. The economic value of 
personalized medicine tests: what we know and what we need to know. Genet Med. 
2014;16(3):251-7. 
8. Phillips KA, Ann Sakowski J, Trosman J, Douglas MP, Liang SY, Neumann P. The economic value of 
personalized medicine tests: what we know and what we need to know. Genet Med. 
2014;16(3):251-7. 
9. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 
2013. https://www.nice.org.uk/process/pmg9  
10. Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of 
HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008;22:2025-
33. 
11. Hughes DA1, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis 
of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics. 
2004;14(6):335-42. 
12. Oosterhoff M, van der Maas ME, Steuten LM. A Systematic Review of Health Economic 
Evaluations of Diagnostic Biomarkers. Appl Health Econ Health Policy. 2016;14(1):51-65. 
13. Roberts S, Barry E, Craig D, Airoldi M, Bevan G, Greenhalgh T. Preventing type 2 diabetes: 
systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with 
and without screening, for pre-diabetes. BMJ Open. 2017;7(11):e017184. 
14. D'Andrea E, Marzuillo C, Pelone F, De Vito C, Villari P. Genetic testing and economic evaluations: 
a systematic review of the literature. Epidemiol Prev. 2015;39(4 Suppl 1):45-50.15Kim SC, 
Newcomb C, Margolis D, Roy J, Hennessy S. Severe cutaneous reactions requiring hospitalization 
in allopurinol initiators: a population-based cohort study. Arthritis Care Res (Hoboken). 
2013;65(4):578-84. 
15. Plumpton CO, Alfirevic A, Pirmohamed M, Hughes DA. Cost effectiveness analysis of HLA-
B*58:01 genotyping prior to initiation of allopurinol for gout. Rheumatology (Oxford). 
2017;56(10):1729-1739. 
16. Ke CH, Chung WH, Wen YH, Huang YB, Chuang HY, Tain YL, Wang YL, Wu CC, Hsu CN. Cost-
effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe 
Cutaneous Adverse Drug Reactions. J Rheumatol. 2017;44(6):835-843. 
17. Dong D, Tan-Koi WC, Teng GG, Finkelstein E, Sung C. Cost-effectiveness analysis of genotyping 
for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in 
Singapore. Pharmacogenomics. 2015;16(16):1781-93. 
18. Chong HY, Lim YH, Prawjaeng J, Tassaneeyakul W, Mohamed Z, Chaiyakunapruk N. Cost-
Effectiveness Analysis of HLA-B*58:01 Genetic Testing Prior to Initiation of Allopurinol Therapy 
to Prevent Allopurinol-Induced SJS/TEN in Malaysian Population. Pharmacogenetics and 
Genomics (in press) 
19. European Parliament and Council of the European Union. Regulation (EC) No 141/2000 of the 
European Parliament and of the Council of 16 December 1999 on orphan medicinal products. 
Official J Eur Communities 22.1.2000 
20. Frey N, Jossi J, Bodmer M, Bircher A, Jick SS, Meier CR, Spoendlin J. The Epidemiology of Stevens-
Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. J Invest Dermatol. 
2017;137(6):1240-1247. 
21. European Medicines Agency. Public summary of opinion on orphan designation [Nle4, D-Phe7]-




22. Lee HY, Walsh SA, Creamer D. Long-term complications of Stevens-Johnson syndrome/toxic 
epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an 
episode of SJS/TEN necessitates multidisciplinary follow-up. Br J Dermatol. 2017;177(4):924-935. 
23. Kim ES, Garnock-Jones KP. Afamelanotide: A Review in Erythropoietic Protoporphyria. Am J Clin 
Dermatol. 2016;17(2):179-85. 
24. http://clinuvel.com/investors/news  
25. Thompson JC, Mealing S, Vetrini D, Wolgen P. The cost effectiveness of afamelanotide for the 
treatment of erythropoietic protoporhyria. Value Health. 2016;19(3):A248-249. 
26. Onakpoya IJ, Spencer EA, Thompson MJ, Heneghan CJ. Effectiveness, safety and costs of orphan 
drugs: an evidence-based review. BMJ Open. 2015;5(6):e007199. 
27. Schuller Y, Hollak CE, Biegstraaten M. The quality of economic evaluations of ultra-orphan drugs 
in Europe - a systematic review. Orphanet J Rare Dis. 2015;10:92. 
28. Kawalec P, Sagan A, Pilc A. The correlation between HTA recommendations and reimbursement 
status of orphan drugs in Europe. Orphanet J Rare Dis. 2016;11(1):122. 
29. Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges 
posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36-42. 
30. Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special 
status for funding? QJM. 2005;98(11):829-36. 
31. Linley WG, Hughes DA. Societal views on NICE, cancer drugs fund and value‐based pricing criteria 
for prioritising medicines: A cross‐sectional survey of 4118 adults in Great Britain. Health Econ. 
2013;22(8):948-64. 
32. Desser AS, Gyrd-Hansen D, Olsen JA, Grepperud S, Kristiansen IS. Societal views on orphan drugs: 
cross sectional survey of Norwegians aged 40 to 67. BMJ. 2010;341:c4715. 
33. Chim L, Salkeld G, Kelly P, Lipworth W, Hughes DA, Stockler MR. Societal perspective on access 
to publicly subsidised medicines: A cross sectional survey of 3080 adults in Australia. PLoS One. 
2017;12(3):e0172971. 
34. Richardson J, Iezzi A, Chen G, Maxwell A. Communal Sharing and the Provision of Low-Volume 
High-Cost Health Services: Results of a Survey. PharmacoEconomics Open. 2017;1:13-23. 
35. Gu Y, Lancsar E, Ghijben P, Butler JR, Donaldson C. Attributes and weights in health care priority 
setting: A systematic review of what counts and to what extent. Soc Sci Med. 2015;146:41-52. 
36. Bosworth R, Cameron TA, DeShazo JR. Is an ounce of prevention worth a pound of cure? 
Comparing demand for public prevention and treatment policies. Med Decis Making. 
2010;30(4):E40-56. 
37. Pirmohamed M, Hughes DA. Pharmacogenetic tests: the need for a level playing field. Nat Rev 
Drug Discov. 2013;12(1):3-4. 
  
  Afamelanotide for erythropoeitic 
protoporphyria 
Genotyping (HLA-B*58:01) to 
prevent allopurinol induced SJS/TEN 
in gout patients 
Disease related factors 
 Incidence Less than 2 in 100,000 people [22] 7 per 10,000 patients prescribed 
allopurinol [15] 
 Clinical  features Most patients experience 
prodromal symptoms (e.g. itching, 
tingling) and symptoms of cutaneous 
phototoxicity (e.g. burning, intense 
pain) within minutes of sun/light 
exposure, and erythema and 
oedema may appear with prolonged 
exposure 
Macules appear and rapidly spread 
and coalesce, leading to epidermal 
blistering, necrosis, and sloughing. 
Epidermal detachment can, in severe 
cases of TEN, lead to large sheets of 
epithelium sliding off the entire body 
 Prognosis Prognosis depends on evolution of 
hepatic disease. Photosensitivity 
significantly impacts quality of life. 
Further complications can include 
gallstones, chronic hepatitis, liver 
failure and vitamin D deficiency 
Patients are at high risk of infection, 
multi-organ failure, and mortality 
(26.5% over the first 30 days [16]). 
Long term sequelae can be ocular, 
cutaneous, oral, pulmonary, renal, 
urogenital/gynaecological, 
gastrointestinal, hepatic, psychiatric 
and psychosocial [23] 
Intervention-related factors 
 Strength of clinical 
evidence 
Clinical development programme, 
including 3 phase III placebo-
controlled randomised controlled 
trials, inclusive of 259 patients [24] 
13 genetic association studies with 
allopurinol-tolerant controls and 239 
cases of SJS/TEN patients [13] 
 Cost per patient €56,404 to €84,606 per annum [25] £55.50 
 Average QALY gain 
per patient 




£697,510 [26] £103 [16] 
 Incremental cost 
effectiveness ratio 
£208,000 to £1.1m per QALY gained 
[26] 
£44,954 per QALY gained [16] 
Table 1. Comparison of the clinical and economic features of a treatment for a rare disease and 
pharmacogenetic test to prevent a rare ADR. 
 
